Physiological Approaches to Increase Biocompatibility of Peritoneal Dialysis

Liberek T. , Topley N. , Jörres A. Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3: 1508–15.

Topley N. , Coles G.A. , Williams J.D. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994; (Suppl 3)14: S21–8.

Breborowicz A. , Martis L. , Oreopoulos D.G. Changes in biocompatibility of dialysis fluid during its dwell in the peritoneal cavity. Perit Dial Int 1995; 15: 152–7.

Dobbie J.W. , Lloyd J.K. , Galla C.A. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1990; 6: 3–12.

Slater N.D. , Cope G.H. , Raftery A.T. Mesothelial hyperplasia in response to peritoneal dialysis fluid: a morphometric study in the rat. Nephron 1991; 58: 466–77.

Slater N.D. , Cope G.H. , Raftery A.T. Peritoneal ultrafiltration after chronic exposure to dialysis fluid. Perit Dial Int 1992; 12: 48–50.

Rennard S.I. , J aurand M. , Bignon J. Role of pleural mesothelial cells in the production of submesothelial connective matrix of lung. Am Rev Respir Dis 1984; 130: 267–74.

Davilla R.M. , Crouch E.C. Role of mesothelial and submesothelial stromal cells in matrix remodelling following pleural injury Am J Pathol 1993; 142: 547–55.

Keane W.F. , Comty C.M. , Verbrugh H.A. Opsonic deficiency of peritoneal dialysis effluent in CAPD. Kidney Int 1984; 25: 539–43.

Vebrugh H.A. , Keane W.F. , Conroy W.E. Bacterial growth and killing in CAPD fluids. J Clin Microbiol 1984; 20: 199–203.

Gallimore B. , Gagnon R.F. , Stevenson M.M. Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice. Nephron 1986; 43: 283–9.

Jörres A. , Jörres D. , Gahl G.M. Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate. Nephron 1991; 58: 276–82.

Duwe A.K. , Vas S.I. , Weatherhead J.W. Effects of the composition of dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun 1981; 33: 130–5.

Bos H.J. , Vlaanderen K. , Van der Meulen J. Peritoneal macrophages in short dwell time effluent show diminished phagocytosis. Perit Dial Int 1988; 8: 199–202.

Buggy B.P. , Schaberg D.R. , Swartz R.D. Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am J Med 1984; 76: 1035–40.

Jörres A. , Topley N. , Steenweg L. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992; 12: 80–5.

Haag-Weber M. , Horl W.H. Impact of continuous ambulatory peritoneal dialysis solutions and clearance of macromolecules on polymorphonuclear neutrophils. Perit Dial Int 1994; 14(Suppl 3): S33–8.

Steinhauer H.B. , Lubrih-Birkner I. , Kluthe R. Effect of amino acid based dialysis solution on peritoneal permeability and prostanoid generation in patients undergoing continuous ambulatory peritoneal dialysis. Am J Nephrol 1992; 12: 61–7.

Goldman M. , Vandenabeele P. , Moulart J. Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 277–80.

Busch T. , Plum J. , Withold W. Intraperitoneal production of inflammatory cytokines and their soluble receptor fractions in CAPD patients without peritonitis. Perit Dial Int 1995; 15(Suppl 1): S24.

Breborowicz A. , Korybalska K. , Karon J. Properties of mesothelial cells exposed to glucose or amino acid based dialysate effluents. Perit Dial Int 1995; 15(Suppl 1): S76.

Veech R.L. The toxic impact of parenteral solutions on the metabolism of cells: a hypothesis for physiological parenteral therapy. Am J Clin Nutr 1986; 44: 519–51.

Veech R.L. The untoward effects of the anions of dialysis fluids. Kidney Int 1988; 34: 587–97.

Wieslander A. , Nordin M.K. , Kjellstrand P.T. Toxicity of peritoneal dialysis fluids on cultured fibroblasts 1–929. Kidney Int 1991; 40: 77–9.

Wieslander A.P. , Nordin M.K. , Martinson E. Heat sterilized PD-fluids impair growth and inflammatory responses of cultured celllines and human leukocytes. Clin Nephrol 1993; 39: 343–8.

Pagel M.D. , Ahmed S. , Vizzo J.E. Acetate and bicarbonate fluctuations and acetate intolerance during dialysis. Kidney Int 1982; 21: 513–18.

Gitomer W.L. , Veech R.L. The accumulation of pyro phosphate by rat hepatocytes. Toxicol Indust Health 1986; 2: 21–34.

Veech R.L. , Gitomer W.L. The medical and metabolic consequences of administration of sodium acetate. Adv Enzyme Regul 1988; 27: 313–43.

Slingeneyer A. , Canaud B. , Mion C. Permanent loss of ultrafiltration capacity of the peritoneum in longterm peritoneal dialysis. An epidemiological study. Nephron 1983; 33: 133–8.

Faller B. , Marichal J.F. Loss of ultrafiltration in continuous ambulatory peritoneal dialysis: a role for acetate. Perit Dial Bull 1984; 4: 10–13.

Rottembourg J. , Issad B. , Langlois P. Loss of ultrafiltration and sclerosing encapsulating peritonitis during CAPD; evaluation of the potential risk factors. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in CAPD. Toronto: Peritoneal Dialysis Bulletin, 1985; 1: 108–17.

Pedersen F.B. , Ryttov N. , Deleuran P. Acetate versus lactate in peritoneal dialysis solutions. Nephron 1985; 39: 55–8.

Nielsen L.H. , Nolph K.D. , Khanna R. Peritoneal sclerosis and ultrafiltration following 3 months of CAPD in a small animal model. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in CAPD. Toronto: Peritoneal Dialysis Bulletin, 1985; 1: 100–6.

Thurn J.R. , Pierpont G.L. , Lidvigsen C.W. D lactate encephalopathy. Am J Med 1985; 79: 717–21.

Richardson R.M.A. , Roscoe J.M. Bicarbonate, L-Iactate and D-Iactate balance in intermittent peritoneal dialysis. Perit Dial Bull 1986; 6: 178–85.

Yasuda T. , Ozawa S. , Shiba C. D-Iactate metabolism in patients with chronic renal failure undergoing CAPD. Nephron 1993; 63: 416–22.

Yu A.W. , Zhou X.J. , Nawab Z.M. Neutrophilic intracellular acidosis induced by conventional, lactate-containing peritoneal dialysis solutions. Int J Artif Organs 1992; 15: 661–5.

Chaimovitz C. , Conforti A. , Doudevani A. The effect of commercial dialysis solutions on cytosolic pH of peritoneal macrophages. Perit Dial Int 1992; 12(Suppl 1): 106.

Liberek T. , Topley N. , Jörres A. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to lowering of intracellular pH. Nephron 1993; 65: 260–5.

Breborowicz A. , Rodela H. , Martis L. Lactate at acid pH is responsible for the decrease in intracellular glutathione of mesothelial cells exposed to dialysis solutions. Perit Dial Int 1995; 15(Suppl 1): S75.

Comstock J.P. , Undenfriend S. Effect of lactate on collagen proline hydroxylase activity in cultured L929 fibroblasts. Proc Natl Acad Sci USA 1970; 66: 552–7.

Breborowicz A. , Martis L. , Oreopoulos D.G. In vitro influence of lactate on function of peritoneal fibroblasts. In: Khanna R. , ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1994; 10: 225–9.

Mahiout A. , Brunkhorst R. Development of a new CAPD solution using the anion pyruvate as buffer improving peritoneal host defence. J Am Soc Nephrol 1994; 5: 421.

Brunkhorst R. , Mahiout A. Pyruvate as non-toxic peritoneal dialysate buffer; maintained mesothelial cell integrity and proliferation. J Am Soc Nephrol 1994; 5: 410.

Brunkhorst R. , Mahiout A. Pyruvate anions neutralize peritoneal dialysate cytotoxicity on cultured human mesothelial cells and peritoneal fibroblasts. Perit Dial Int 1995; 15(Suppl 1): S76.

Yamamoto T. , Sakakura T. , Yamakawa M. Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis. Nephron 1992; 60: 324–9.

Jörres A. , Gahl G.M. , Topley N. In vitro bio-compatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose polymer-based solutions. Nephrol Dial Transplant 1994; 9: 785–90.

Kristensen S.R. , Pedersen F.B. Cytotoxicity testing of two CAPD dialysis fluids in a model system of quiescent fibroblasts. Nephrol Dial Transplant 1993; 8: 163–7.

Topley N. , Kaur D. , Jörres A. Human peritoneal mesothelial cell viability and cytokine synthesis in bicarbonate vs. lactate peritoneal dialysis fluids. J Am Soc Nephrol 1994; 5: 481.

Yatzidis H. Enhanced ultrafiltration in rabbits with bicarbonate glycylglycine peritoneal dialysis solution. Perit Dial Int 1993; 13: 302–6.

Martis L. , Burke R. , Deleo M. Evaluation of glycylglycine/bicarbonate buffered solutions for PD. Perit Dial Int 1995; 15(Suppl 1): S79.

Feriani M. , Dissegna D. , La Greca G. Continuous ambulatory peritoneal dialysis with bicarbonate buffer -a pilot study. Perit Dial Int 1993; 13(Suppl 2): S88–91.

Feriani M. , Passlick-Deetjen J. , Brown C. An open controlled randomized clinical trial with bicarbonate CAPD solutions: interim results. J Am Soc Nephrol 1994; 5: 414.

Schambye H.T. , Pedersen F.B. , Wang P. Bicarbonate is not the ultimate answer to the bioincompatibility problem of CAPD solutions: a cytotoxicity test of CAPD solutions and effluents. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 42–6.

Schambye H.T. , Pedersen F.B. , Christensen H.K. The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios. Perit Dial Int 1993; 13(Suppl 2): S116–18.

Williamson D.H. , Lund P. , Krebs H.A. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J 1967; 103: 514–27.

Sistare F.D. , Haynes R.C. The interaction between the cytosolic pyridine nucleotide redox potential and gluconeogenesis from lactate/pyruvate in isolated rat hepatocytes. J Biol Chem 1985; 260: 12748–53.

Veech R.L. , Lawson J.W.R. , Cornell N.W. Cytosolic phosphorylation potential. J Biol Chem 1979; 254: 6538–47.

Breborowicz A. , Witowski J. , Knapowski J. In vitro study of the mechanism of potassium transport into human mesothelial cells. I: Effect of hyperosmolality. Perit Dial Int 1993; 13: 201–7.

Gotloib L. , Wajsbrot V. , Shostack A. Experimental approach to peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3): S6–11.

Sistare F.D. , Haynes R.C. Acute stimulation by glucocorticoids of gluconeogenesis from lactate/pyruvate in isolated hepatocytes from normal and adrenalectomized rats. J Biol Chem 1985; 23: 12754–60.

Ramos J.M. , Heaton A. , McGurk J.G. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983; 35: 20–3.

Lindholm B. , Bergstrom J. Nutritional requirements of peritoneal dialysis patients. In: Gokal R. , Nolph K.D. , eds. The textbook of peritoneal dialysis. Dordrecht: Kluwer Academic, 1994: 443–72.

De Fijter C.W.H. , Verbrugh H.A. , Peters E.D.J. In vitro exposure to the currently available fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993; 39: 75–80.

Breborowicz A. , Rodela H. , Oreopoulos D.G. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992; 41: 1280–5.

Yamada K. , Miyahara Y. , Hamaguchi K. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 1994; 42: 354–61.

Kumano K. , Manalaysay M.T. , Hyodo T. Inhibition of peritoneal mesothelial cell growth by glycosylated albumin. Perit Dial Int 1995; 15(Suppl 1): S68.

Mahiout A. , Brunkhorst R. Human mesothelial cells produce 72 kD-gelatinase during exposure to advanced glycosylated collagen. Perit Dial Int 1995; 15(Suppl 1): S11.

Kumano K. , Schiller-Moran B. , Hjelle J.T. Effects of high glucose levels on cell proliferation and TGFbeta expression in cultured rat mesothelial cells. J Am Soc Nephrol 1993; 4: 410.

Wang T. , Chen Y.G. , Ye R.G. Enhanced expression of TGF -betal by peritoneal macrophages in CAPD patients. Perit Dial Int 1995; 15(Suppl 1): S35.

Hain H. , Kessel M. Aspects of new solutions for peritoneal dialysis. Nephrol Dial Transplant 1987; 2: 67–72.

Mistry C.D. , Gokal R. Icodextrin in peritoneal dialysis: early development and clinical use. Perit Dial Int 1994; 14(Suppl 2): S13–21.

Liberek T. , Topley N. , Mistry C.D. Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993; 13: 104–11.

Gokal R. , Mistry C. , Peers E. A United Kingdom multicenter study of icodextrin in continuous ambulatoryperitoneal dialysis. Perit Diallnt 1994; 14(Suppl 2): S22–7.

Davies D.S. Kinetics of icodextrin. Perit Dial Int 1993; 13(Suppl 2): S45–50.

Martis L. , Burke R. , Klein E. Evaluation of a peptide based solution for peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2): S92–4.

Krediet R.T. , Imholz AL. T. , Lameire N. The use of peptides in peritoneal dialysis fluids. Perit Dial Int 1994; 14(Suppl 3): S152–7.

Di Paolo N. , Sacchi G. , Buoncristiani U. The morphology of the peritoneum in APD patients. In: Maher J.F. , Winchester J.F. , eds. Frontiers in peritoneal dialysis. New York: Field, Rich and Associates, 1986: 11–19.

Dobbie J.W. Pathology of peritoneum. In: Bengmark S. , ed. The peritoneum and peritoneal access. London: Wright, 1989: 42–52.

Heimbürger O. , Waniewski J. , Werynski A. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 485–506.

Lewis S. , Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1991; 11: 14–21.

Beelen R.H.J. , van der Meulen J. , Verbrugh H. CAPD, a permanent state of peritonitis: a study on peroxidase activity. In: Maher J.F. , Winchester J.F. , eds. Frontiers in peritoneal dialysis. New York: Field, Rich and Associates, 1986: 524–30.

Bos H.J. , Meyer F. , De Veld J.C. Peritoneal dialysis fluid induces change of mononuclear phagocyte proportions. Kidney Int 1989; 36: 20–6.

Bos H.J. , Struijk D.G. , Tuk C.W. Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence. Nephron 1991; 59: 508–9.

Davies S.J. , Suassuna J. , Ogg C.S. Activation of immunocompetent cells in the peritoneum of patients treated with CAPD. Kidney Int 1989; 36: 661–8.

Khanna R. Peritoneal dialysis in diabetic end-stage renal disease. In: Gokal R. , Nolph K.D. , eds. The text book of peritoneal dialysis. Dordrecht: Kluwer Academic, 1994: 639–59.

Selgas R. , Lopez-Rivas A. , Alvaro F. Insulin influence (used as an additive to dialysate) on the mitogenic-induced effect of the peritoneal effluent in CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1989; 5: 161–4.

Gotloib L. , Shostack A. , Bar Sella P. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Bull 1987; 7: 148–55.

Betjes M.G.H. , Bos H.J. , Krediet R.T. The mesothelial cells in CAPD effluents and their relation to peritonitis incidence. Perit Dial Int 1991; 11: 22–6.

Lipkin G.W. , Forbes M.A. , Cooper E.H. Hyaluronic acid metabolism and its clinical significance in patients treated by continuous peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 357–60.

Hamura Y. , Ito A. , Okada Y. Hyaluronic acid metabolism in inflamed mesenterium of guinea pig. Res Commun Chem Pathol Pharmacol 1989; 66: 311–26.

Yung S. , Coles G.A. , Williams J.D. The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 1994; 46: 527–33.

Laurent T.C. , Fraser J.R.E. The properties and turnover of hyaluronan. In: Functions of the proteoglycans (Ciba Foundation Symposium 124). Chichester: John Wiley and Sons, 1986: 9–24.

Butler D.M. , Vitti G.F. , Leizer T. Stimulation of the hyaluronic acid levels of human synovial fibroblasts by recombinant human tumor necrosis factor-alpha, tumor necrosis factor-beta (lymphotoxin), interleukin 1-alpha and interleukin 1-beta. Arthritis Rheum 1988; 31: 1281–9.

Bachem M.G. , Riess U. , Melchior R. Transforming growth factors stimulate chondroitin sulphate and hyaluronate synthesis in cultured rat liver fatstoring cells. FEBS Lett 1989; 257: 134–7.

Engstrom-Laurent A. , Feltelius N. , Hallgren R. Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells. Ann Rheum Dis 1985; 44: 614–20.

Engstrom-Laurent A. , Hallgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985; 44: 83–8.

Nettelbladt O. , Tengblad A. , Hallgren R. Lung accumulation of hyaluronan parallels pulmonary edema in experimental alveolitis. Am J Physiol 1989; 257: L379–84.

Laurent T.C. , Fraser J.R.E. Hyaluronan. FASEB J 1992; 6: 2397–404.

Weigel P.H. , Fuller G.M. , LeBoeuf R.D. A model for the role of hyaluronic acid and fibrin in early events during the inflammatory response and wound healing. J Theor Biol 1986; 119: 219–26.

Greenwald R.A. , Moy W.W. Effect of oxygen-derived free radicals on hyaluronic acid. Arthritis Rheum 1980; 223: 455–61.

Suzuki Y. , Yamaguchi T. Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release. Agents Actions 1993; 38: 32–7.

Akatsuka M. , Yamamoto Y. , Tobetto K. Suppressive effects of hyaluronic acid on elastase release from rat peritoneal leukocytes. J Pharm Pharmacol 1993; 45: 110–14.

Wieczorowska K. , Breborowicz A. , Martis L. Protective effect of hyaluronic acid against peritoneal injury. Perit Dial Int 1995; 15: 81–3.

Breborowicz A. , Wieczorowska K. , Martis L. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67: 346–50.

Abatangelo G. , Martelli M. , Vecchia P. Healing of hyaluronic-enriched wounds: histological observations. J Surg Res 1983; 35: 410–16.

Adzick N.S. , Longaker M.T. Scarless fetal healing. Therapeutic implications. Ann Surg 1992; 215: 3–7.

Gambaro G. , Fracasso A. , Re G. Glycosamino glycans improve peritoneal transport and fibrosis in rats with peritoneal sclerosis induced by diethyl-exylphthalate. J Am Soc Nephrol 1994; 5: 448.

Fracasso A. , Gambaro G. , Bazzato G. Glycosaminoglycans ameliorate peritoneal permselectivity in long term CAPD patients. J Am Boc Nephrol 1994; 5: 446.

Gambaro G. , Cavazzana A.O. , Luzi P. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285–291.

Dobbie J.W. Ultrastructure and pathology of the peritoneum in peritoneal dialysis. In: Gokal R. , Nolph K.D. , eds. The textbook of peritoneal dialysis. Dordrecht: Kluwer Academic, 1994: 17–44.

Breborowicz A. , Wieczorowska K. , Witowski J. Phosphatidylcholine and chondroitin sulphate in peritoneal dialysis fluids to preserve membrane function. Perit Dial Int 1994; 14(Suppl 3): S139–44.

Taylor J.E. , Scott N. , Bridges A. Lipidperoxidation and antioxidants in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1992; 12: 252–6.

Omata M. , Sanaka T. , Matsuzawa T. Increased cellular fibronectin (EDA(+)FN) in CAPD patients and its relation to oxidant injury. Perit Dial Int 1995; 15(Suppl 1): S80.

Radeke H.H. , Meier B. , Topley N. Interleukin 1alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 1990; 37: 767–75.

Thannickai V.J. , Hassoum P.M. , White A.C. Enhanced H2O2 release from bovine pulmonary artery endothelial cells induced by TGF -betal. Am J Physiol 1993; 265: L622–6.

Wolff S.P. , Jiang zY , Hunt J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339–52.

Breborowicz A. , Patrikarea A. , Martis K. NAcetyl-cysteine and L-2-oxothiazolidine-4-carboxylate as precursors of intracellular glutathione in human peritoneal mesothelial cells. Blood Purif, in press.

Tsan M.F. , Phillips P.G. 1-2-Oxothiazolidine-4 carboxylate protects cultured endothelial cells against hyperoxia induced injury. Inflammation 1988; 12: 113–21.

Sala R. , Moriggi E. , Corvasce G. , Morelli D. Protection by N-acetyl-cysteine against pulmonary endothelial cell damage induced by oxidant injury. Eur Respir J 1993; 6: 440–6.

Breborowicz A. , Witowski J. , Martis L. Enhancement of viability of human peritoneal mesothelial cells with glutathione precursor: L-2-oxothiazolidine4-carboxylate. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1993; 10: 21–4.

Honda S. , Matsuo M. Relationship between the cellular glutathione level and in vitro life span of human diploid fibroblasts. Exp Gerontol 1988; 23: 81–6.

Oddera S. , Silvestri M. , Sacco O. N-Acetylcysteine enhancesin vitro the intracellular killing of Staphylococcus aureus by human alveolar macrophages and blood polymorphonuclear leukocytes and partially protects phagocytes from self-killing. J Lab Clin Med 1994; 124: 293–301.

Brisseau G.F. , Marshall J.C. , Cheung P.Y.C. N-Acetylcysteine differentially modulates macrophage activation by lipopolysaccharide. Burg Forum 1993; XLIV: 16–18.

Di Paolo N. , Sacchi G. , Vanni L. Implant of autologous mesothelial cells in animals and a peritoneal dialysis patient. Int J Artif Organs 1989; 12: 485–501.

Di Paolo N. , Vanni L. , Sacchi G. Autologous implant of peritoneal mesothelium in rabbits and man. Clin Nephrol 1990; 34: 179–84.

Shockley T.R. , Jackman R.W. , Nagy J.A. Systemic delivery of a recombinant protein by ex vivo mesothelial cell gene therapy. J Am Boc Nephrol 1994; 5: 476.